A quicker way to get vaccine and oncology drugs to market: Stephen Trevisan, President & CEO, Accelovance




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: A quicker way to get vaccine and oncology drugs to market: Stephen Trevisan, President & CEO, Accelovance
Released on: June 06, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    What makes Accelovance the CRO of choice in the vaccine and oncology space? Currently able to do studies faster, more cost effectively and get good quality data, Stephen Trevisan, President & CEO of award-winning niche Contract Research Organization talks to Fintan Walton at BioEurope in Turin about their plans.
  • Summary
  • Transcript
  • Participants
  • Company
What makes Accelovance the CRO of choice in the vaccine and oncology space? Currently able to do studies faster, more cost effectively and get good quality data, Stephen Trevisan, President & CEO of award-winning niche Contract Research Organization talks to Fintan Walton at BioEurope in Turin about their plans.
What makes Accelovance the CRO of choice in the vaccine and oncology space? Currently able to do studies faster, more cost effectively and get good quality data, Stephen Trevisan, President & CEO of award-winning niche Contract Research Organization talks to Fintan Walton at BioEurope in Turin about their plans.
Stephen Trevisan
Accelovance
Accelovance